Compare Pfizer Inc (PFE) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Invesco NASDAQ 100 ETF — how do they compare? Pfizer Inc trades at $28.16 (market cap $158.56B), while Invesco NASDAQ 100 ETF trades at $309.27 (market cap $113.40B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays a 6.18% dividend while Invesco NASDAQ 100 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Invesco NASDAQ 100 ETF for 54 Days on average.
| PFE | QQQM | |
|---|---|---|
Market Cap | $158.56B | $113.40B |
Volume | 44,138,282 | 2,866,236 |
Sector | Health | Broad Market / Factor |
52-Week High | $29.02 | $312.76 |
52-Week Low | $23.67 | $229.87 |
Typical Hold Time | 158 Days | 54 Days |
Enterprise Value | $210.06B | — |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
QQQM (Invesco NASDAQ 100 ETF) trades at $309.27, down 0.88% on the day, with a bullish technical signal from moving averages. The ETF tracks the NASDAQ-100 index with a low 0.15% expense ratio. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% during Q2 2026. Technical indicators show support at $305 and resistance at $311, with neutral oscillator readings suggesting balanced momentum.
The outlook remains positive given the NASDAQ-100's growth exposure and cost efficiency versus QQQ. Risks include market concentration in technology stocks and potential volatility from macroeconomic factors. Institutional accumulation and favorable expense structure support long-term positioning, though investors should monitor index composition changes and broader market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
